Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA)

[1]  Miguel Castelo-Branco,et al.  Testing the excitation/inhibition imbalance hypothesis in a mouse model of the autism spectrum disorder: in vivo neurospectroscopy and molecular evidence for regional phenotypes , 2017, Molecular Autism.

[2]  S. Kagami,et al.  A Proton Magnetic Resonance Spectroscopic Study in Autism Spectrum Disorder Using a 3-Tesla Clinical Magnetic Resonance Imaging (MRI) System: The Anterior Cingulate Cortex and the Left Cerebellum , 2017, Journal of child neurology.

[3]  Alcino J. Silva,et al.  Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1 , 2016, Neurology.

[4]  J. Satoh,et al.  Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis , 2016, Biomarker Research.

[5]  Jonathan Green,et al.  Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT). , 2016, JAMA psychiatry.

[6]  C John Evans,et al.  Quantification of γ‐aminobutyric acid (GABA) in 1H MRS volumes composed heterogeneously of grey and white matter , 2016, NMR in biomedicine.

[7]  M. Castelo‐Branco,et al.  GABA deficiency in NF1 , 2016, Neurology.

[8]  A. Ishii,et al.  Strength of ERK1/2 MAPK Activation Determines Its Effect on Myelin and Axonal Integrity in the Adult CNS , 2016, The Journal of Neuroscience.

[9]  W. Newman,et al.  Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only , 2016, EBioMedicine.

[10]  L. Parkes,et al.  Quantitative measurement of blood flow in paediatric brain tumours—a comparative study of dynamic susceptibility contrast and multi time-point arterial spin labelled MRI , 2016, The British journal of radiology.

[11]  Q. Ling,et al.  Statins and the brain: New perspective for old drugs , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  Alcino J. Silva,et al.  A randomized placebo‐controlled lovastatin trial for neurobehavioral function in neurofibromatosis I , 2016, Annals of clinical and translational neurology.

[13]  M. Castelo‐Branco,et al.  GABA deficiency in NF 1 A multimodal [ 11 C ]-flumazenil and spectroscopy study , 2016 .

[14]  Genevera I. Allen,et al.  Resting state functional MRI reveals abnormal network connectivity in neurofibromatosis 1 , 2015, Human brain mapping.

[15]  Ilya M. Veer,et al.  Functional Connectivity Changes and Executive and Social Problems in Neurofibromatosis Type I , 2015, Brain Connect..

[16]  S Lovestone,et al.  Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes , 2015, Translational Psychiatry.

[17]  S. Vansteelandt,et al.  Increasing the power of the Mann‐Whitney test in randomized experiments through flexible covariate adjustment , 2015, Statistics in medicine.

[18]  I. Noens,et al.  Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1 , 2015, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[19]  A. Malfitano,et al.  Statins in neurological disorders: an overview and update. , 2014, Pharmacological research.

[20]  D. Yousem,et al.  Diffusion Tensor Imaging of Neurofibromatosis Bright Objects in Children with Neurofibromatosis Type 1 , 2014, The neuroradiology journal.

[21]  Y. Mechref,et al.  Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase , 2014, Nature Neuroscience.

[22]  Luke Bloy,et al.  GABA estimation in the brains of children on the autism spectrum: Measurement precision and regional cortical variation , 2014, NeuroImage.

[23]  C. John Evans,et al.  Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA , 2014, NeuroImage.

[24]  L. Soorya,et al.  Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. , 2014, Research in autism spectrum disorders.

[25]  R. Emsley,et al.  Neurofibromatosis Type 1 and Autism Spectrum Disorder , 2013, Pediatrics.

[26]  C. Catsman-Berrevoets,et al.  Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial , 2013, The Lancet Neurology.

[27]  A. Straube,et al.  Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1 , 2013, BMC Neurology.

[28]  A. Stemmer-Rachamimov,et al.  Nf1 Loss and Ras Hyperactivation in Oligodendrocytes Induce NOS-Driven Defects in Myelin and Vasculature , 2013, Cell reports.

[29]  K. Yeom,et al.  Reduced Cerebral Arterial Spin-Labeled Perfusion in Children with Neurofibromatosis Type 1 , 2013, American Journal of Neuroradiology.

[30]  T. Hassan,et al.  Blood and Brain Glutamate Levels in Children with Autistic Disorder. , 2013 .

[31]  Miguel Castelo-Branco,et al.  GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. , 2013, Brain : a journal of neurology.

[32]  R. Emsley,et al.  Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population‐based study , 2013, Developmental medicine and child neurology.

[33]  Alcino J. Silva,et al.  Alterations in White Matter Microstructure in Neurofibromatosis-1 , 2012, PloS one.

[34]  L. Ferrucci,et al.  Longitudinal changes in brain function related to statin use , 2012, Alzheimer's & Dementia.

[35]  Michael P. Milham,et al.  Lovastatin regulates brain spontaneous low-frequency brain activity in Neurofibromatosis type 1 , 2012, Neuroscience Letters.

[36]  G. Gioia,et al.  Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. , 2011, Pediatric neurology.

[37]  Kenji Mori,et al.  Non-Invasive Evaluation of the GABAergic/Glutamatergic System in Autistic Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3 Tesla Instrument , 2011, Journal of autism and developmental disorders.

[38]  Paola Mengotti,et al.  Altered white matter integrity and development in children with autism: A combined voxel-based morphometry and diffusion imaging study , 2011, Brain Research Bulletin.

[39]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[40]  J. Burgos,et al.  Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. , 2011, Journal of Alzheimer's disease : JAD.

[41]  S. Huson,et al.  Birth incidence and prevalence of tumor‐prone syndromes: Estimates from a UK family genetic register service , 2010, American journal of medical genetics. Part A.

[42]  Stephen M Smith,et al.  Correspondence of the brain's functional architecture during activation and rest , 2009, Proceedings of the National Academy of Sciences.

[43]  N. Filippini,et al.  Group comparison of resting-state FMRI data using multi-subject ICA and dual regression , 2009, NeuroImage.

[44]  P. Thuras,et al.  GABAA Receptor Downregulation in Brains of Subjects with Autism , 2009, Journal of autism and developmental disorders.

[45]  Alcino J. Silva,et al.  Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning , 2008, Cell.

[46]  I. Weiler,et al.  Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome , 2008, Journal of developmental and behavioral pediatrics : JDBP.

[47]  Alcino J. Silva,et al.  Effect of Simvastatin on Cognitive Functioning in Children with Neurofibromatosis Type 1 a Randomized Controlled Trial , 2022 .

[48]  Diane C. Chugani,et al.  Diffusion Tensor Imaging of Frontal Lobe in Autism Spectrum Disorder , 2008, Cerebral cortex.

[49]  R. Buchert,et al.  Reduced thalamic 18F-flurodeoxyglucose retention in adults with neurofibromatosis type 1 , 2008, Nuclear medicine communications.

[50]  Talma Hendler,et al.  Accelerated maturation of white matter in young children with autism: A high b value DWI study , 2007, NeuroImage.

[51]  J. Zschocke,et al.  Effects of cholesterol and simvastatin treatment in patients with Smith–Lemli–Opitz syndrome (SLOS) , 2007, Journal of Inherited Metabolic Disease.

[52]  D. Graveron-Demilly,et al.  Java-based graphical user interface for the MRUI quantitation package , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[53]  Geraldine Dawson,et al.  Head circumference and height in autism: A study by the collaborative program of excellence in autism , 2006, American journal of medical genetics. Part A.

[54]  Esben Thade Petersen,et al.  Model‐free arterial spin labeling quantification approach for perfusion MRI , 2006, Magnetic resonance in medicine.

[55]  S. Leucht,et al.  The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials , 2006, Neuropsychopharmacology.

[56]  Alcino J. Silva,et al.  The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.

[57]  Kathryn N North,et al.  The nature and frequency of cognitive deficits in children with neurofibromatosis type 1 , 2005, Neurology.

[58]  Mark H Johnson,et al.  The emergence of the social brain network: Evidence from typical and atypical development , 2005, Development and Psychopathology.

[59]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[60]  Stephen M. Smith,et al.  Probabilistic independent component analysis for functional magnetic resonance imaging , 2004, IEEE Transactions on Medical Imaging.

[61]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[62]  C. McDougle,et al.  Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[63]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[64]  L. Kluwe,et al.  Treatment of ADHD in neurofibromatosis type 1 , 2002, Developmental medicine and child neurology.

[65]  Stephen M. Smith,et al.  A global optimisation method for robust affine registration of brain images , 2001, Medical Image Anal..

[66]  G L Shulman,et al.  INAUGURAL ARTICLE by a Recently Elected Academy Member:A default mode of brain function , 2001 .

[67]  J. Farmer.  Pleiotropic effects of statins , 2000, Current atherosclerosis reports.

[68]  J. Bodfish,et al.  Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. , 1999, The New England journal of medicine.

[69]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[70]  A. Dale,et al.  Cortical Surface-Based Analysis II: Inflation, Flattening, and a Surface-Based Coordinate System , 1999, NeuroImage.

[71]  James D. A. Parker,et al.  The Revised Conners' Parent Rating Scale (CPRS-R): Factor Structure, Reliability, and Criterion Validity , 1998, Journal of abnormal child psychology.

[72]  E. Reiman,et al.  Positron Emission Tomography in Children With Neurofibromatosis-1 , 1997, Journal of child neurology.

[73]  D. Perani,et al.  Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[74]  D. van Ormondt,et al.  SVD-based quantification of magnetic resonance signals , 1992 .

[75]  Michael J. Bernstein.  The use of therapeutic plasmapheresis for neurological disorders. National Institutes of Health Consensus Development Conference. , 1988, Transfusion medicine reviews.

[76]  W. Schofield.  Overview and update. , 1987 .

[77]  D. Look,et al.  Time Saving in Measurement of NMR and EPR Relaxation Times , 1970 .